Creoptix AG closes CHF8m financing round Swiss drug discovery analytics specialist Creoptix AG has raised CHF8m in a Series C financing for commercial expansion. more ➔
AMR: GARDP and Entasis Therapeutics start...Entasis Therapeutics Inc (Waltham, USA) and non for profit organisation GARDP (Geneva, Switzerland) have initiated Phase III testing of the novel antibiotic zoliflodacin to treat infections with the … more ➔
BASF broadens biotech business by Isobioni...BASF SE has strengthened its capabilities in recombinant production of natural ingredients by acquiring Dutch Isobionics BV and collaborating with Conagen Inc. more ➔
2nd ECP Summer Summit at Henkel HQ, Düsse...290 participants from 18 nations at the late summer edition of the European Chemistry Partnering in Düsseldorf High level or participation from Southern and Eastern EuropeAttendance record and more … more ➔
Gut bacterial enzyme keeps inflammation aw...An antimicrobial molecule produced by the human microbiota gut may help fight drug-resistant infections. more ➔
Tacalyx GmbH raises €7m in seed fundingGerman Tacalyx GmbH has baged €7m in seed financing to generate antibodies that home in on tumour-antigene specific carbohydrates (TACAs) of glycans. more ➔
Evotec and Takeda enter drug discovery dea...Evotec SE and Takeda Pharmaceutical Company Ltd have entered a strategic drug discovery collaboration potentially worth $850m. Under the agreement, Evotec will develop at least five small molecule discovery … more ➔
EMA greenlights new medicinesAt its September meeting, the EMAs CHMP recommended three innovative medicines for EU market approval. more ➔
New malaria lead kills 99.9% of pathogensDutch and US researchers have re-engineered non-druggable compounds that block the transmission and metabolism of the malaria parasite Plasmodium falciparum. more ➔
Versantis raises CHF16m in Series B financ...Swiss Versantis AG has raised money in order to advance its liver detoxifying candidate VS-01 from ongoing Phase Ia trials to initial Phase IIa efficacy proof. more ➔